提醒

Mirum Pharmaceuticals Inc... (MIRM)

NasdaqGM: MIRM · 即時價格 · USD

99.83

-0.81 (-0.80%)

收盤時： Aug 17, 2026, 3:59 PM

-0.80% (1D)

買價	76.76
市值	6.09B
營收 (ttm)	618.07M
淨利（ttm）	-860.21M
貝塔	0.51
EPS (ttm)	-13.98
本益比（ttm）	n/a
正向 PE	-287.97
P/B (ttm)	-620.06
P/S (ttm)	9.85
Earnings Date	Nov 4, 2026

賣價	134.63
成交量	381,116
20 日平均成交量	843,218
打開	99.93
上一頁關閉	100.64
日間範圍	99.23 - 101.43
52 週範圍	63.23 - 130.00
分析師	Strong Buy
目標價	137 (37.23%)
股利	n/a
Ex-股利日期	n/a

關於MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. ...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Jul 18, 2019

員工 433

證券交易所 NasdaqGM

股票代號 MIRM

網站 https://www.mirumpharma.com

完整的公司簡介

財務表現

Mirum Pharmaceuticals 在 2025 年的營收為 521.31M，較前一年的 336.89M 增加 54.74%。淨利為 -23.36M，較前期減少 -73.43%。

財務報表

分析師預測

根據14 分析師評等，MIRM股票的平均評等為「Strong Buy」。 12個月股價預測為137，與最新價格相比為上漲空間的37.23%。

股票預測

獲利驚喜

Mirum Pharmaceuticals 已於 Aug 5, 2026 公布季度財報：

營收的 $176.24M 錯過估計 $0, 與 37.92% YoY 成長.

EPS 的 -0.8 錯過估計 -0.05, 與 -566.67% YoY 下降.

下次財報發布

Mirum Pharmaceuticals Inc. 定於發布財報 Nov 4, 2026, 在市場交易時間內。
分析師預估營收 ... 升級

新聞動態

4 天前 · Simply Wall St.

Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next

Mirum Pharmaceuticals reported second-quarter 2026 results showing a net loss of US$67.23 million (US$1.06 per share) and a six-month net loss of US$857.38 million (US$14.03 per share), while also upd...

5 天前 · Motley Fool

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript

LIVMARLI sales surged 46% while management raised full-year guidance to $680M–$700M.

1 週前 · Investor's Business Daily

Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath.

Insmed stock led a biotech rally Thursday, catapulting 34% on solid second-quarter sales for its new lung disease drug, Brinsupri.

1 週前 · Zacks

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

1 週前 · Stocktwits

Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%

The firm said the U.S. Food and Drug Administration’s request for an additional Phase 3 trial of Volixibat to treat a liver disease is expected to delay the program.

第 1 頁，共 2 頁

Mirum Pharmaceuticals Inc... (MIRM)